Evidence map›Paper›PMID 33071712›Full record

ArticleAdvanced functional materials2020

A Patch of Detachable Hybrid Microneedle Depot for Localized Delivery of Mesenchymal Stem Cells in Regeneration Therapy.

KangJu Lee, Yumeng Xue, Junmin Lee, Han-Jun Kim, Yaowen Liu, Peyton Tebon, Einollah Sarikhani, Wujin Sun, Shiming Zhang, Reihaneh Haghniaz and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 165 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Microneedle-Assisted Cell Delivery and Therapy.Research (Washington, D.C.) · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Microneedles at the Forefront of Next Generation Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  16. Article
  17. Review
  18. Photothermal-Responsive Soluble Microneedle Patches for Meibomian Gland Dysfunction Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 3 countries.

KangJu LeeDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Yumeng XueDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Junmin LeeDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Han-Jun KimDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Yaowen LiuCollege of Food Science, Sichuan Agricultural University, Yaan, 625014, China.
Peyton TebonDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Einollah SarikhaniDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Wujin SunDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Shiming ZhangDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Reihaneh HaghniazDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Betül Çelebi-SaltikDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Xingwu ZhouDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Serge OstrovidovDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Samad AhadianDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Nureddin AshammakhiDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Mehmet R DokmeciDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
Ali KhademhosseiniDepartment of Bioengineering and Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USSichuan Agricultural University · CN

Funding

Microengineered Osteons for Bone Tissue EngineeringR01AR057837 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2010 to 2018
$5.1M
Engineering personalized micro-tumor ecosystemsU01CA214411 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI, SENGUPTA, SHILADITYA · 2017 to 2021
$3.5M
Hemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0M
Engineering a naturally derived and highly adhesive surgical sealantR01EB023052 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANNABI, NASIM, KHADEMHOSSEINI, ALI · 2017 to 2022
$2.4M
Targeted chemotherapy delivery and captureR01EB024403 · NIBIB · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2017 to 2020
$2.2M
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the HipR01AR072613 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B, YANG, YUNZHI · 2018 to 2022
$2.2M
Rapid 3D bioprinting of biomimetic vascularized tissue constructsR01EB021857 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, DOKMECI, MEHMET REMZI · 2016 to 2019
$2.1M
High-Throughput Microenvironment Regulation for ChondrogenesisR01AR066193 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALSBERG, EBEN, KHADEMHOSSEINI, ALI · 2015 to 2020
$2.1M
Multifunctional dressing for treatment of diabetic woundsR01GM126831 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI DOKMECI, MEHMET REMZI, TAMAYOL, ALI · 2018 to 2021
$1.3M
Smart wound dressing for treating chronic diabetic ulcersR21EB022403 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2016 to 2017
$484k
NCI NIH HHS U01 CA214411NHLBI NIH HHS R01 HL137193NIAMS NIH HHS R01 AR057837NIAMS NIH HHS R01 AR066193NIAMS NIH HHS R01 AR072613NIBIB NIH HHS R01 EB021857NIBIB NIH HHS R01 EB023052NIBIB NIH HHS R01 EB024403NIBIB NIH HHS R21 EB022403NIGMS NIH HHS R01 GM126831
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) have been widely used for regenerative therapy. In most current clinical applications, MSCs are delivered by injection but face significant issues with cell viability and penetration into the target tissue due to a limited migration capacity. Some therapies have attempted to improve MSC stability by their encapsulation within biomaterials; however, these treatments still require an enormous number of cells to achieve therapeutic efficacy due to low efficiency. Additionally, while local injection allows for targeted delivery, injections with conventional syringes are highly invasive. Due to the challenges associated with stem cell delivery, a local and minimally invasive approach with high efficiency and improved cell viability is highly desired. In this study, we present a detachable hybrid microneedle depot (d-HMND) for cell delivery. Our system consists of an array of microneedles with an outer poly(lactic-co-glycolic) acid (PLGA) shell and an internal gelatin methacryloyl (GelMA)-MSC mixture (GMM). The GMM was characterized and optimized for cell viability and mechanical strength of the d-HMND required to penetrate mouse skin tissue was also determined. MSC viability and function within the d-HMND was characterized

Indexed as

biodegradable polymerGelMA hydrogelmesenchymal stem cellmicroneedleregenerative therapy

Identifiers

PMID33071712
PMCPMC7567343
OpenAlexW3018000454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.